Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Zwingers

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Blood|June 1, 1997
Prognostic impact of the serum levels of soluble CD23 in B-cell chronic lymphocytic leukemiaW U Knauf, B Ehlers, B Mohr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
Significance of cytogenetic findings for the clinical outcome in patients with T-cell lymphoma of angioimmunoblastic lymphadenopathy typeB Schlegelberger, T Zwingers, K Hohenadel, et al.
Leukemia|April 1, 1987
A prospective multicenter trial with human recombinant alpha 2c-interferon in hairy cell leukemia before and after splenectomyH Pralle, T Zwingers, S Boedewadt, et al.
Onkologie|February 1, 1987
[Primary treatment of hairy cell leukemia with low-dose human recombinant interferon-alpha-2c (Hr-IFn alpha 2c) in comparison with therapy following splenectomy. Interferon (IFn-alpha 2c) in HCL before or after splenectomy]H Pralle, T Zwingers, S Boedewadt, et al.
Blood|March 1, 1990
Clinical implications of increased plasma levels of CD8 in patients with hairy cell leukemiaA D Ho, M Grossman, L Trümper, et al.
Blood|July 1, 1991
Effective natural interferon-alpha therapy in recombinant interferon-alpha-resistant patients with hairy cell leukemiaP von Wussow, H Pralle, H K Hochkeppel, et al.
European Journal of Medical Research|September 3, 2002
Predictors of treatment failure during highly active antiretroviral therapy (racing trial)A Masuhr, M Mueller, V Simon, et al.
British Journal of Cancer|April 1, 2016
Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR studyW Janni, N Harbeck, B Rack, et al.
Oncology|September 1, 1997
Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancerA R Hanauske, A Korfel, M Perker, et al.
Blood|November 11, 1999
Clinicopathogenetic significance of chromosomal abnormalities in patients with blastic peripheral B-cell lymphoma. Kiel-Wien-Lymphoma Study GroupB Schlegelberger, T Zwingers, L Harder, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Blood|June 1, 1997
Prognostic impact of the serum levels of soluble CD23 in B-cell chronic lymphocytic leukemiaW U Knauf, B Ehlers, B Mohr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
Significance of cytogenetic findings for the clinical outcome in patients with T-cell lymphoma of angioimmunoblastic lymphadenopathy typeB Schlegelberger, T Zwingers, K Hohenadel, et al.
Leukemia|April 1, 1987
A prospective multicenter trial with human recombinant alpha 2c-interferon in hairy cell leukemia before and after splenectomyH Pralle, T Zwingers, S Boedewadt, et al.
Onkologie|February 1, 1987
[Primary treatment of hairy cell leukemia with low-dose human recombinant interferon-alpha-2c (Hr-IFn alpha 2c) in comparison with therapy following splenectomy. Interferon (IFn-alpha 2c) in HCL before or after splenectomy]H Pralle, T Zwingers, S Boedewadt, et al.
Blood|March 1, 1990
Clinical implications of increased plasma levels of CD8 in patients with hairy cell leukemiaA D Ho, M Grossman, L Trümper, et al.
Blood|July 1, 1991
Effective natural interferon-alpha therapy in recombinant interferon-alpha-resistant patients with hairy cell leukemiaP von Wussow, H Pralle, H K Hochkeppel, et al.
European Journal of Medical Research|September 3, 2002
Predictors of treatment failure during highly active antiretroviral therapy (racing trial)A Masuhr, M Mueller, V Simon, et al.
British Journal of Cancer|April 1, 2016
Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR studyW Janni, N Harbeck, B Rack, et al.
Oncology|September 1, 1997
Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancerA R Hanauske, A Korfel, M Perker, et al.
Blood|November 11, 1999
Clinicopathogenetic significance of chromosomal abnormalities in patients with blastic peripheral B-cell lymphoma. Kiel-Wien-Lymphoma Study GroupB Schlegelberger, T Zwingers, L Harder, et al.
Pageof 5